ORIGINAL ARTICLE
Year : 2020  |  Volume : 22  |  Issue : 1  |  Page : 26-30

Virological and immunological profile of HIV patients on first-line antiretroviral therapy in north central Nigeria: a retrospective study


1 Department of Medicine, Jos University Teaching Hospital, Jos; AIDS Prevention Initiative in Nigeria (APIN), Jos University Teaching Hospital, Jos, Nigeria
2 AIDS Prevention Initiative in Nigeria (APIN), Jos University Teaching Hospital, Jos, Nigeria
3 AIDS Prevention Initiative in Nigeria (APIN), Jos University Teaching Hospital, Jos; Department of Paediatrics, Jos University Teaching Hospital, University of Jos, Jos, Nigeria
4 Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria
5 AIDS Prevention Initiative in Nigeria (APIN), Jos University Teaching Hospital, Jos; Department of Obstetrics and Gynaecology, Jos University Teaching Hospital, University of Jos, Jos, Nigeria

Correspondence Address:
Dr. Nathan Y Shehu
Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria and AIDS Prevention Initiative in Nigeria (APIN), Jos University Teaching Hospital, Jos
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jomt.jomt_23_19

Rights and Permissions

Background and Objectives: The use of Highly Active Antiretroviral Therapy (HAART) has dramatically improved the quality of life and overall survival of HIV patients. UNAIDS has set a target of viral suppression for 90% of those treated by 2020 in order to end the HIV epidemic. We set out to determine patients’ virologic and immunological response after medium term first-line ART. Methods: This retrospective study was done between April 2017 and May 2018 at the AIDS Prevention Initiative in Nigeria (APIN)-supported HIV clinic of the Jos University Teaching Hospital (JUTH), north central Nigeria. Included in this analysis were patients who had been on either TDF/FTC/EFV or AZT/FTC/NVP consistently for at least 12 months and who had at least 95% adherence based on pharmacy drug pick up. Data were analysed using SPSS version 23.0. Results: A total of 301 patients who met the inclusion criteria were studied of which 187 (62.1%) were females and the overall mean (SD) age was 40±9 years. There were 204 (67.8%) patients on AZT/FTC/NVP while 97 (32.2%) were on TDF/FTC/EFV. Overall, the CD4 count increased from a median (IQR) baseline of 201 cells/mm3 by the end of 12 months of HAART. Or was it 24 months you used? (112–284) to 488 cells/mm3 by the end of 12 months of HAART (344.5–628.0) P = <0.001. Their overall virological suppression was 86.7%, but was higher for the TDF/FTC/EFV arm 92.8% compared to the AZT/3TC/NVP arm 83.8% (P = 0.03). Conclusion: Overall, there was good virologic suppression and immunological response of patients on first-line ART. This suggests that with good adherence the UNAIDS target of viral suppression for 90% of those treated is achievable.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed376    
    Printed45    
    Emailed0    
    PDF Downloaded86    
    Comments [Add]    

Recommend this journal